Bayer AG NA

Research Bayer AG NA (BAYN) on Bullrun: market cap EUR 47.20B, dividend yield 0.2%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 47.20B; dividend yield is 0.2%.

Peer valuation comparison

Latest dividend yield is 0.23% versus a Healthcare sector median of 2.11% (89.1% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 45.58B-EUR 3.62BEUR 3.44B58.8%n/aEUR 6.67BEUR 36.45BEUR 25.95B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24EUR 47.20Bn/a0.2%0.11

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.11 EUR, yield 0.2%.

About Bayer AG NA

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Bayer AG NA's market cap?

Bayer AG NA's market capitalization is EUR 47.20B.

Does Bayer AG NA pay a dividend?

Bayer AG NA has a dividend yield of 0.2%.

What does Bayer AG NA do?

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.